secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001104659-23-026761
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE extends Oral BETi option to April 30, 2023; regains Nasdaq minimum bid price compliance
--------------------------------------------------------------------------------

- Extended option term for Oral BETi Compounds to April 30, 2023; paid Tay $250k non-refundable fee.
- Fee will be deducted from $4.0M upfront if option exercised.
- Received Nasdaq notice on Feb 28, 2023 that bid price ≥$1.00 for 10 consecutive business days through Feb 27, 2023.
- Regained compliance with Nasdaq Rule 5550(a)(2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/0001104659-23-026761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/tm237985d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer